Open Access

Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials

  • Authors:
    • Wei-Ting Lin
    • Chien-Ming Chao
    • Cheng-Yao Lin
    • Ya-Ting Hsu
    • Sheng-Yen Hsiao
    • Teng-Song Weng
  • View Affiliations

  • Published online on: October 11, 2024     https://doi.org/10.3892/mco.2024.2791
  • Article Number: 93
  • Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Acute myeloid leukemia (AML) is one of the most frequent forms of acute leukemia and the second most common leukemia subtype in adults. In 2020, the incidence of AML in the United States was estimated to be ~4 cases per 100,000 adults. The FMS‑like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutation are major prognostic indicators of AML. They are more frequently observed in younger AML patients (aged <60 years), likely due to their association with de novo. Additionally, these mutations have a stronger negative impact on survival in younger patients. Therefore, quizartinib and gilteritinib are second‑generation FLT3 inhibitors that are frequently applied for treating patients with AML. However, to the best of our knowledge, few studies have compared the efficacy of second‑generation FLT3 inhibitors for AML treatment. Therefore, the present study conducted a comprehensive search for studies on the efficacy and safety of FLT3 inhibitors across PubMed, Embase, the Cochrane Library and ClinicalTrials.gov. The search criteria were limited to randomized controlled trials (RCTs). Subsequently, a meta‑analysis was performed on a total of five randomized controlled trials, involving 1,543 participants in total, using a random‑effects model. In each RCT, compared to the salvage chemotherapy used in the control group, the groups that received second‑generation FLT3 inhibitors experienced significant improvements in overall survival (hazard ratio, 0.717; 95% CI, 0.604‑0.850; P<0.001). In addition, overall survival was found to be consistent across the different types of second‑generation FLT3 inhibitors used and different types of AML. The risks associated with a prolonged heart‑rate corrected QT interval (QTc) interval were next evaluated. Compared with the salvage chemotherapy used in the control group, the second‑generation FLT3 inhibitor group exhibited a significantly higher risk of having a prolonged QTc interval (odds ratio, 6.311; 95% CI, 3.061‑13.013; P<0.001). In conclusion, these findings suggest that second‑generation FLT3 inhibitors can improve the overall survival of patients with AML. However, QTc prolongation is a potential adverse effect that should be monitored.
View Figures
View References

Related Articles

Journal Cover

December-2024
Volume 21 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin W, Chao C, Lin C, Hsu Y, Hsiao S and Weng T: Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials. Mol Clin Oncol 21: 93, 2024.
APA
Lin, W., Chao, C., Lin, C., Hsu, Y., Hsiao, S., & Weng, T. (2024). Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials. Molecular and Clinical Oncology, 21, 93. https://doi.org/10.3892/mco.2024.2791
MLA
Lin, W., Chao, C., Lin, C., Hsu, Y., Hsiao, S., Weng, T."Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials". Molecular and Clinical Oncology 21.6 (2024): 93.
Chicago
Lin, W., Chao, C., Lin, C., Hsu, Y., Hsiao, S., Weng, T."Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials". Molecular and Clinical Oncology 21, no. 6 (2024): 93. https://doi.org/10.3892/mco.2024.2791